Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Scott Koerber

Clinical Cardiac Electrophysiology Independence, MO Doctor of Osteopathy

NPI 1013229863 CMS profile 477875

19600 E 39Th St S Ste 215, Independence, MO 64057

Open in the dashboard

General payments

$57,635

844 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$79,214 paid to institutions, not to them · program years 2021–2023

Through program year 2025, Scott Koerber of Independence, MO is reported in the CMS Open Payments database as having received $57,635 across 844 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $79,214 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 79th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,155 134
2024 General $6,218 145
2023 General $18,273 136
2022 General $12,414 171
2021 General $5,211 130
2020 General $1,464 62
2019 General $3,899 66

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Scott Koerber
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Scott Koerber were reported at $10,155. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Scott Koerber Clinical Cardiac Electrophysiology median Middle half National median
2019 $3,899 $2,361 $585–$8,260 $163
2020 $1,464 $993 $247–$4,351 $114
2021 $5,211 $1,185 $326–$4,739 $132
2022 $12,414 $2,073 $554–$6,789 $149
2023 $18,273 $2,568 $759–$8,159 $160
2024 $6,218 $2,557 $703–$7,403 $164
2025 $10,155 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $15,930 162 payments
  2. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $10,005 51 payments
  3. Boston Scientific Corporation $8,546 258 payments
  4. Biosense Webster, Inc. $7,994 101 payments
  5. Medical Device Business Services, Inc. $7,875 7 payments
  6. Biotronik Inc. $1,770 18 payments
  7. Medtronic, Inc. $900 45 payments
  8. Medtronic Vascular, Inc. $876 22 payments
  9. Amgen Inc. $471 31 payments
  10. Atricure, Inc. $326 5 payments
  11. Other $2,941 144 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $24,405 15 payments
  2. Food and Beverage $20,128 816 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $11,500 7 payments
  4. Travel and Lodging $950 3 payments
  5. Education $651 3 payments
Products named General payments · program years 2019–2025
  1. Carto 3 $14,368 67 payments
  2. LifeVest $10,005 51 payments
  3. ADVISOR $5,499 5 payments
  4. ENSITE $5,417 9 payments
  5. General - Therapies $2,500 1 payment
  6. EnSite Precision Cardiac Mapping System $1,920 8 payments
  7. WATCHMAN Access System $1,029 48 payments
  8. EMBLEM MRI S-ICD $617 28 payments
  9. Carto 3 System $563 10 payments
  10. ACCOLADE SR $546 20 payments
  11. Other $14,735 645 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

2,080

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$630,965

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

41.5%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 546 $479,164
Xarelto Rivaroxaban Brand 95 $90,583
Jardiance Empagliflozin Brand 17 $15,897
Entresto Sacubitril/Valsartan Brand 12 $15,506
Dofetilide Generic 95 $14,340
Amiodarone Hcl Generic 310 $3,523
Flecainide Acetate Generic 84 $2,928
Metoprolol Succinate Generic 226 $2,640
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 43 $984
Carvedilol Generic 160 $883

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 59 billing codes

Paid by Medicare

$289,430

Medicare's payments for the services billed

Medicare patients

736

Average age 77

Services billed

4,036

352 women, 384 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 72%
Ischemic heart disease 54%
Heart failure 50%
Arthritis 50%
Chronic kidney disease 42%
Diabetes 41%
Depression 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $104
$104 — —
Repatha
  • Amgen Inc. $74
$74 — —
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $63
$63 — —
VERQUVO
  • Merck Sharp & Dohme Corporation $54
$54 — —
EVKEEZA
  • Regeneron Healthcare Solutions, Inc. $49
$49 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

844 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record